Foralumab

Foralumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	CD3 epsilon
Clinical data
ATC code	none;
Identifiers
CAS Number	946415-64-1 ;
ChemSpider	none;
UNII	J43DL56H6M;
	(what is this?) (verify)

Foralumab (TZLS-401), being researched by Tiziana Life Sciences^[1]) is a fully human monoclonal antibody that binds to CD3 epsilon of the T cell receptor-CD3 complex.^[2] It is currently being studied in a randomized, double-blind placebo-controlled, multicenter dose-ranging study in a nasal formulation in patients with non-active secondary progressive multiple sclerosis (SPMS).^[1]

^ ^a ^b Tiziana Life Sciences LTD (2024-03-15). A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients (Report). clinicaltrials.gov.
^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103" (PDF). WHO Drug Information.

[:0-1] Tiziana Life Sciences LTD (2024-03-15). A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients (Report). clinicaltrials.gov.

[2] World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103" (PDF). WHO Drug Information.

[1]

[2]